Other substances

Indinavir

An HIV protease inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Indinavir is used for treatment and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). It acts as an antiretroviral protease inhibitor (LiverTox).

Indinavir on DrugBank
Indinavir on PubChem
Indinavir on Wikipedia

Marketed as

CRIXIVAN (INDINAVIR SULFATE)

CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server	in silico	4.55	Predicted to bind a SARS-CoV-2 protein structural feature.	Aug/11/2020
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins Spike protein 3CLpro In silico	in silico	4.07	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Sep/07/2020
Potential protease inhibitors and their combinations to block SARS-CoV-2 3CLpro TMPRSS2 Cathepsin B Cathepsin L Small molecule In silico	in silico	3.22	Predicted to inhibit the host's cathepsins B and L.	Sep/14/2020
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach 3CLpro RdRpol Small molecule In silico	in silico	2.45	Predicted to bind both SARS-CoV-2 3C-like protease and RNA-dependent RNA polymerase. It also possesses predicted good bioavailability.	Oct/26/2020
Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CLpro through high-throughput virtual screening and molecular dynamics simulation 3CLpro Small molecule In silico Screening	in silico	4.83	Predicted to inhibit SARS-CoV-2 3C-like protease.	Mar/07/2021

AI-suggested references

Link	Publication date
Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.	Mar/03/2022
Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study.	Mar/01/2022
Whole genome analysis and homology modeling of SARS-CoV-2 Indian isolate reveals potent FDA approved drug choice for treating COVID-19.	Apr/01/2022
Anti-HIV drug repurposing against SARS-CoV-2	Apr/21/2020
Identification of potential antivirals against SARS-CoV-2 using virtual screening method.	Feb/10/2021
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study	May/13/2020
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease	Apr/12/2020
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation	Aug/03/2021
The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness.	Oct/10/2020
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.	Sep/21/2020
Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction	Mar/25/2022
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.	Mar/15/2021
Discovery of New Hydroxyethylamine Analogs against 3CLpro Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies	Jun/18/2020

Export (.csv)